


Adult Hypersensitivity (HSR)/Allergic Reaction Management

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

Any signs or symptoms of hypersensitivity reaction (HSR)/allergic reaction, **notify Responding Provider¹ and activate the appropriate emergency response process for your area.**



¹ Appropriate providers may include: Primary attending physician, ordering provider, covering attending physician or advanced practice provider, nocturnal provider, etc.

² Fever is defined as a temperature of $> 38.3^{\circ}\text{C}$ **or** $\geq 38^{\circ}\text{C}$ for 1 hour or longer

³ Some chemotherapy/biotherapy agents have a need to avoid corticosteroids. Corticosteroids should still be given in cases of severe allergic reactions.

⁴ Documentation:


- Use HSR/Allergy orders to document management utilized for an individual patient
- Document event as an Observed Adverse Drug Reaction (ADR)

⁵ Hypotension defined as a systolic blood pressure (SBP) < 90 mmHg or a drop in SBP of more than 20 mmHg from baseline

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

Any signs or symptoms of hypersensitivity reaction (HSR)/allergic reaction, **notify Responding Provider¹ and activate the appropriate emergency response process for your area.**

PRESENTING SYMPTOMS



¹ Appropriate providers may include: Primary attending physician, ordering provider, covering attending physician or advanced practice provider, nocturnal provider, *etc.*

² Hypotension defined as a systolic blood pressure (SBP) < 90 mmHg or a drop in SBP of more than 20 mmHg from baseline

³ Administer epinephrine IM into the antero-lateral mid-third portion of the thigh is preferred. The deltoid can be considered as an administration site if unable to administer in the thigh during an emergency. Administration via IM route is preferred regardless of platelet count.

⁴ Some chemotherapy/biotherapy agents have a need to avoid corticosteroids. Corticosteroids should still be given in cases of severe allergic reactions.

⁵ Documentation:

- Use HSR/Allergy orders to document management utilized for an individual patient
- Document event as an Observed Adverse Drug Reaction (ADR)

Adult Hypersensitivity (HSR)/Allergic Reaction Management

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- Berg, K. M., Cheng, A., Panchal, A. R., Topjian, A. A., Aziz, K., Bhanji, F., ... Lavonas, E. J. (2020). Part 7: Systems of care: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation*, 142(16 Suppl 2), S580-S604. <https://doi.org/10.1161/CIR.0000000000000899>
- Finney, A., & Rushton, C. (2007). Recognition and management of patients with anaphylaxis. *Nursing Standard*, 21(37), 50-57. <https://doi.org/10.7748/ns2007.05.21.37.50.c4560>
- Golden, D. B. K., Wang, J., Waserman, S., Akin, C., Campbell, R. L., Ellis, A. K., ... Wang, J. (2024). Anaphylaxis: A 2023 practice parameter update. *Annals of Allergy, Asthma & Immunology*, 132(2), 124-176. <https://doi.org/10.1016/j.anai.2023.09.015>
- Gomes, E. R., & Demoly, P. (2005). Epidemiology of hypersensitivity drug reactions. *Current Opinion in Allergy and Clinical Immunology*, 5(4), 309-316. <https://doi.org/10.1097/01.all.0000173785.81024.33>
- Lenz, H. J. (2007). Management and preparedness for infusion and hypersensitivity reactions. *The Oncologist*, 12(5), 601-609. <https://doi.org/10.1634/theoncologist.12-5-601>
- Muraro, A., Worm, M., Alviani, C., Cardona, V., DunnGalvin, A., Garvey, L. H., ... European Academy of Allergy and Clinical Immunology, Food Allergy, Anaphylaxis Guidelines Group. (2022). EAACI guidelines: Anaphylaxis (2021 update). *Allergy*, 77(2), 357-377. <https://doi.org/10.1111/all.15032>
- Zanotti, K. M., & Markman, M. (2001). Prevention and management of antineoplastic-induced hypersensitivity reactions. *Drug Safety*, 24(10), 767-779. <https://doi.org/10.2165/00002018-200124100-00005>

Adult Hypersensitivity (HSR)/Allergic Reaction Management

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.*

DEVELOPMENT CREDITS

This practice consensus statement is based on majority opinion of the Adult Hypersensitivity Reaction workgroup at the University of Texas MD Anderson Cancer Center for the patient population. These experts included:

Core Development Team Leads

Huifang “Linda” Lu, MD, PhD (Rheumatology, Clinical Immunology)
Laura Michaud, PharmD (Pharmacy)

Workgroup Members

Ariel Callanta, RN (ATC)
Tennille Campbell, BSN, RN (ATC – Woodlands)
Kristin Doyle, MSN, RN (RCC Administration)
Carmen Escalante, MD (General Internal Medicine)
Olga N. Fleckenstein, BS♦
Thoa Kazantsev, MSN, RN, OCN♦
Cori Kopecky, MSN, RN (ATC – Sugarland)
Ellen Manzullo, MD (General Internal Medicine)
Lilli Ann Mauricio, RN (RCC – Woodlands)

Brooke A. Ngo, BSN, RN (ATC – West Houston)
Amy Pai, PharmD♦
Rina Patel, PharmD (Pharmacy Clinical Programs)
Goley Richardson, MSN, RN, OCN (Nursing Administration)
Leonard Roes, PharmD (Pharmacy Inpatient)
Shirlene Tabao, MSN, RN (ATC – West Houston)
Praise Thomas, MSN, RN (Med/Surg Onc – League City)
Juliana Toro, BSN, RN (ATC)

♦ Clinical Effectiveness Development Team